October 24, 2023
Stenoa’s STEMI Platform Demonstrates Remarkable Impact on Time-to-Treatment and False Activation Rates at TCT 2023
SAN FRANCISCO, California, October 24, 2023 - Today, at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference, innovative abstracts were presented demonstrating the transformative impact of Stenoa’s cloud-based ST-Segment Elevation Myocardial Infarction (STEMI) care coordination platform on the urgent management of patients with an acute myocardial infarction. The studies conducted at the McGill University Health Centre in Montreal, Canada, revealed significant improvements in STEMI treatment time components and a remarkable reduction in false activation rates of the cardiac catheterization laboratory.
Timely coronary artery reperfusion remains the most important life-saving treatment for patients with a STEMI. Recent data from the United States’ largest national STEMI registry has demonstrated that only 17% of patients requiring transfer to a percutaneous coronary intervention (PCI)-capable center were treated within guideline-directed time goals. The first Stenoa study presented at TCT 2023, titled “Impact of a Cloud-Based Care Coordination Platform on Door-To-Balloon Time Components in Patients with ST-Elevation Myocardial Infarction,” was a retrospective cohort study including 180 patients that demonstrated an over 20% statistically significant reduction in all pre-cardiac catheterization laboratory time components with the deployment of Stenoa, and a trend towards an over 10% reduction in first medical contact to reperfusion time. This data showcases Stenoa’s effectiveness in optimizing care coordination and secure communication across the STEMI care pathway.
False activations of the cardiac catheterization laboratory is a common issue, with an over 25% occurrence in the United States, that can accrue unnecessary expenses, decrease hospital efficiency, and increase healthcare personnel burnout. The second study, titled “Impact of a Cloud-Based Care Coordination Platform on False Activations of the Cardiac Catheterization Laboratory,” demonstrated that through systematic case validation on Stenoa, the McGill University Health Centre was able to reduce the overall rate of unnecessary team mobilization by over 49%, highlighting Stenoa’s efficacy in optimizing healthcare resource allocation.
TCT is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the world's largest conference specializing in interventional cardiovascular medicine. Its 35th Conference is taking place from October 23 to 26 at the Moscone Center in San Francisco, California. Investigators presented data from two studies that assessed Stenoa’s impact on patient care and resource utilization. Full-length manuscripts are forthcoming.
Stenoa’s STEMI platform is available now to tertiary and community hospitals across North America, and further large multicenter studies are underway to confirm its impact on clinical outcomes.
Stenoa Inc. is a healthcare technology company focused on delivering innovative solutions that streamline care coordination and improve patient outcomes. Stenoa's STEMI care coordination platform revolutionizes the way hospitals manage cardiac emergencies by providing real-time, data-driven insights to emergency medical teams. To learn more, visit https://stenoa.com.